Search Results for: CLSN
These are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street research calls this Monday morning.Baker Hughes Inc. (NYSE: BHI) Reiterated Hold at Argus. Biogen Idec...
Published:
Last Updated:
Source: Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall St. research notes this Wednesday.American Campus Communities Inc. (NYSE: ACC) raised to Buy at...
Published:
Last Updated:
Celsion Corp. (NASDAQ: CLSN) watched its shares make an incredible gain on Tuesday after it received an even bigger upgrade from Oppenheimer. This came on the heels of new findings in its Liver...
Published:
Last Updated:
Source: ThinkstockCelsion Corp. (NASDAQ: CLSN) was one of the more recent biotech implosions we have monitored. The company’s situation looked dire, and still does on a static basis. Now comes...
Published:
Last Updated:
Source: ThinkstockThe biotech sector is full of companies which will have great wins and horrible flops. The latter is the case today for Celsion (NASDAQ: CLSN). In fact, if you just look at the...
Published:
October 29, 2013: U.S. markets opened higher Tuesday morning following the report on PPI which showed inflation remaining very low and indicating that the FOMC meeting which began today will...
Published:
Last Updated:
Investors in the biotech and biohealth space generally are taking on much more risk than in the likes of most Dow and S&P 500 stocks. That means they will demand more potential upside for that...
Published:
Last Updated:
Late Thursday and early Friday morning, one Dow 30 stock, the country's second-largest package delivery service, a lidar maker and a small-cap pharmaceutical maker are scheduled to report quarterly...
Published:
Clearside Biomedical has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Clearside Biomedical has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Clearside BioMedical saw its shares make an incredible gain to start the week after the firm announced positive topline results from its late-stage trial.
Published:
Last Updated:
Clearside Biomedical expects to price 4 million shares in the range of $14 to $16 per share in an initial public offering valued up to more than $73 million.
Published:
Last Updated:
Clearside Biomedical shares were dropping early on Thursday after the company released data from its midstage clinical trial of Eylea for diabetic macular edema.
Published:
Last Updated:
Clearside Biomedical has filed with the U.S. Securities and Exchange Commission regarding a secondary offering worth up to more than $86 million.
Published:
Last Updated:
Clearside Biomedical expects to price more than 7 million shares at $7 per share for an initial public offering valued up to nearly $58 million.
Published:
Last Updated: